Scientists from Oxford have taken another step along the frustrating route to an effective malaria vaccine. This autumn, Vasee Moorthy of Oxford University's Department of Clinical Medicine, working with scientists at the Medical Research Council's Laboratories in the Gambia, began trials of new DNA-based vaccines against the malaria parasite Plasmodium falciparum. The vaccines, developed by Adrian Hill and colleagues in the same department, have been in phase I trials of safety and immunogenicity in healthy volunteers in Britain since August 1999. But this is the first time vaccines of this type have been tested in Africa, where malaria kills a million people, mostly children, every year.
The first trials in the Gambia, like the Oxford trial, are funded by the Wellcome Trust and will look at the safety of the new vaccines and the size of the immune response they evoke in healthy adult men. "Most people who grow up in an endemic area develop substantial natural immunity," says Hill, "but it takes too long to protect young children. If we could convert the immune system of a one-year-old into the immune system of a tenyear-old, we could very substantially reduce malaria mortality."
Parasitic diseases present particular problems for vaccine development. Plasmodium falciparum is a complex organism with a multistage life cycle spent partly in the guts and salivary glands of mosquitoes and partly in the liver and blood of human beings. At each stage of its life cycle it expresses different proteins, allowing it to play 'now you see me, now you don't' with the human immune system. Since the 1980s vaccines have been developed in laboratories all over the world, based on 30 or more likelylooking proteins, but so far none has evoked a strong enough immune response to form the basis of a malaria prevention programme.
Even if it is only partially effective, it could save many lives
The Oxford vaccine differs from previous candidates in a number of ways. First, Hill and his colleagues realised that they needed to target the most effective component of the immune response. In malaria, that turned out to be not the antibody response, the target of vaccines against many other diseases, but the cell-mediated response. While antibodies neutralise foreign antigens by binding to them, cytotoxic T cells, or killer cells, are also produced during infections to seek and destroy infected cells. To stimulate the cell-mediated response, Hill decided to use a DNA vaccine rather than the more conventional protein or peptide products. Injected DNA -the exact sequence chosen to correspond to an antigen that looks like a promising candidate -enters the cells of the host and makes the proteins that will trigger the immune response.
Finally, the team used a novel belt-and-braces approach called heterologous prime-boost immunisation. This involves injecting the same antigen in two different forms of vaccine one after another -an approach Hill originally tried in some desperation when none of the individual vaccines under test in his lab worked well enough on its own. The result was spectacular, providing mice with a high level of protection against the malaria parasite. "That looked so attractive a few years ago, not only in malaria but in other areas such as HIV, that we thought it was important to see if it worked in people as well," says Hill.
The two vaccines both contain the complete gene sequence that codes for a parasite surface protein called TRAP (thrombospondinrelated adhesion protein, or anonymous protein), one of the family of proteins that enables the parasite to stick to human cells before invading them. It is expressed both during the sporozoite stage of the parasite's life cycle, the form that infected mosquitoes inject into humans with each bite, and early in the subsequent liver stage. The vaccine also contains several fragments of five other antigens expressed by liver-stage parasites. Hill's team identified these short peptide epitopes as the targets of cytotoxic T cells found in the blood of Africans immune to malaria.
When the parasites first arrive in the liver and enter its cells they are relatively few in number, and the victim has yet to show symptoms of illness. Once they have taken up residence in the cells, they divide rapidly before bursting out into the bloodstream in huge numbers. Hill's goal is to produce a vaccine that will stimulate cytotoxic T cells to destroy all the infected cells in the liver before the parasite has a chance to multiply.
As well as the DNA vaccine, injected into the muscle, the second component of the 'prime-boost' strategy is a recombinant viral vaccine called modified vaccinia virus Ankara (MVA), engineered to include DNA sequences for the malaria epitopes and TRAP, and injected into the skin. This nonreplicating virus, which has never been used in recombinant form before, was safely used two decades ago in a smallpox immunisation programme. The trials in the UK over the past year have tested each vaccine separately. Both proved safe, and both evoked an immune response. Trials of the two vaccines in combination are still under way. "We were sufficiently encouraged to go ahead in the Gambia," says Hill. "It will be interesting to compare the strength of the response in people who have never been infected and in people whose immune systems have seen the parasite before." By the end of the year, Moorthy hopes to have tested each vaccine separately as well as the two in combination in a small group of volunteers.
The next step will be to test the efficacy of the vaccine against the parasite itself. "If all goes well, we plan to vaccinate another group of volunteers in the UK and challenge them with malaria sporozoites, using a drug-sensitive strain of malaria," says Hill. While this approach may sound risky, it has already been successfully used with a very different candidate vaccine known as RTS,S, developed by SmithKline Beecham Biologicals together with the Walter Reed Army Institute of Research in the US and others. The RTS,S vaccine is a protein-based vaccine used with a novel immunostimulatory adjuvant, and has now moved on to field trials, also in the Gambia. RTS,S protected the majority of vaccinated volunteers, but this protection appears to last for months rather than years. The vaccine's developers now plan to test prime-boost strategies with RTS,S to see if that can improve its performance.
Before they embark on largescale vaccination programmes, those in charge of public health in countries where malaria is endemic will want to see evidence that vaccines protect a substantial proportion of the vulnerable population, that they are long-lasting, and that they do not themselves cause illness. But even if the DNA vaccine "is only partially effective, it could save many lives," says Hill. "And it should be easier to boost immunity that is already present than to try to create it from scratch."
Georgina Ferry is a freelance science writer based in Oxford, UK.
Cheats and poachers beware. Multi-locus genotype analyses, which have been widely used to assign individuals to the particular populations they are most likely to have originated from, have come to the aid of suspicious fishing competition judges in Finland. When presented with an unusually large salmon the judges were concerned that the 5.5 kg specimen may have come from the local fishmonger and not the competition lake. So they contacted biologist Craig Primmer and his team at the department of ecology and systematics at the University of Helsinki. Salmon in the competition lake -Lake Saimaa -spend their whole life in freshwater and are maintained artificially by hatchery stock since hydroelectric power plants destroyed their spawning grounds in the 1950s, and only rarely reach this size.
The team began by collecting tissue samples from the suspect fish, Lake Saimaa salmon and individuals from three other Nordic populations.
The team chose microsatellite region analysis because of the highly polymorphic loci in many species. Seven loci were chosen and three analyses were carried out. The results revealed that the Saimaa salmon were quite distinctive from the other populations with much lower genetic diversity at these loci. But the suspect fish failed to show these distinctive characteristics and after all the analyses the team informed the competition judges that they estimated the salmon was 600 times more likely to come from a fishery outside Lake Saimaa.
When confronted with this evidence the fisherman confessed that he had bought the salmon at a local fish shop and criminal charges were laid. Primmer believes these techniques may be helpful in other disputes about the origin of individual animals, such as poaching. 
Fish or foul?
Local fish: genotype analysis has helped identify a rogue salmon presented to judges in a Finnish fishing competition on Lake Saimaa. (Photo: Jorma Piironen).
